
The Manager/Sr. Manager, Clinical Quality Assurance provides quality oversight for Phase 1–4 clinical trials to support compliance with Good Clinical Practice (GCP), applicable regulatory requirements, and company standards. This role partners with internal teams, clinical investigator sites, and service providers to identify and mitigate quality risks, conduct and coordinate audits, strengthen clinical quality systems, and support inspection readiness.
· Conducts QA oversight of clinical project activities to ensure compliance with GCP requirements and other relevant US and international regulations and industry standards.
· Supports internal quality programs and procedures to promote and facilitate the adoption of optimized quality system elements within clinical sciences and related functions.
· Oversees risk monitoring and mitigation strategies at protocol and program levels.
· Develops clinical audit schedules and facilitates the selection of contract auditors to support the clinical audit program.
· Leads or participates in assessments and audits of external clinical investigator sites and vendors (CROs, clinical laboratories, IRBs, etc) to ensure patient safety and data integrity.
· Supports the evaluation and determination of acceptability of internal systems and processes, including Trial Master Files and related data and document systems/types (e.g., protocols, protocol amendments, investigator brochures, informed consent forms, clinical study reports, etc).
· May deliver training on GCP concepts and procedures.
· Supports key quality processes, metrics and indicators to measure, trend, and improve quality determinants of GCP operations.
· Effectively communicates progress and issue resolution to appropriate internal/external stakeholders.
· Supports regulatory inspections as the clinical quality representative.
· Promotes a culture of quality, innovation and operational excellence.
· Ability to travel domestically and internationally approximately 10–20% of the time.
· It is imperative that REGENXBIO employees embody our core values by working collaboratively, building strong relationships and using clear communication to meet shared objectives.
We are looking for someone who thrives in a collaborative, patient-focused environment with the following skills:
· BS in scientific discipline
· Minimum of 7 years of experience in a Quality Assurance / Quality Systems / Clinical QA position in a regulated biopharma / biologics / cellular therapy / gene therapy environment
· Must have direct job experience in a Clinical QA role.
· Practical knowledge of US and international GCP regulations
· Excellent interpersonal skills and ability to effectively interact with and influence different functional groups at multiple levels of the company.
· Excellent oral and written communication skills for effectively interfacing with internal and external stakeholders.
· Strong initiative and project management skills
· Must have excellent attention to detail and time management skills as well as the ability to manage multiple priorities with aggressive timelines and changing priorities
At REGENXBIO, we're committed to fostering an environment where people can do meaningful work, grow professionally, and make an impact. Our core values - trust, accountability, perseverance, and innovation - drive everything we do.
We offer a comprehensive and competitive benefit and compensation package that includes market-competitive salaries, an annual bonus program, education assistance, paid caregiver leave, a retirement plan with employer match, stock options at all levels, summer hours, and more. The estimated compensation range for this role is $120,000 - $155,000 annually. The actual salary offered to the final candidate depends on factors such as relevant work experience, skills, education, and years of experience.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.